Current good manufacturing practice production of an oncolytic recombinant vesicular stomatitis viral vector for cancer treatment

Human Gene Therapy

Volumn 22, Issue 4, 2011, Pages 489-497

  Ausubel, L J ^a   Meseck, M ^b   Derecho, I ^a   Lopez, P ^a   Knoblauch, C ^a   McMahon, R ^a   Anderson, J ^a   Dunphy, N ^a   Quezada, V ^a   Khan, R ^a   Huang, P ^a   Dang, W ^a   Luo, M ^a   Hsu, D ^a   Woo, S L C ^b   Couture, L ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING PROTEIN; CHEMOKINE; VIRUS VECTOR;

ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CANCER PATIENT; CANCER SURVIVAL; CELL MIGRATION; CONTROLLED STUDY; FOOD AND DRUG ADMINISTRATION; GOOD MANUFACTURING PRACTICE; HERPES VIRUS; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; NEOPLASM; NONHUMAN; NUCLEOTIDE SEQUENCE; PHASE 1 CLINICAL TRIAL (TOPIC); PLAQUE FORMING CELL; RAT; SCALE UP; TUMOR NECROSIS; VESICULAR STOMATITIS VIRUS; VIRUS RECOMBINANT; VIRUS REPLICATION; VIRUS STRAIN;

ANIMALS; BIOTECHNOLOGY; CELL CULTURE TECHNIQUES; CELL LINE; CHROMATOGRAPHY, ION EXCHANGE; CRICETINAE; GENETIC VECTORS; HEK293 CELLS; HUMANS; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ULTRAFILTRATION; VESICULAR STOMATITIS INDIANA VIRUS;

MAMMALIA; MURINAE; RATTUS; VESICULAR STOMATITIS VIRUS;

EID: 79954510865     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2010.159     Document Type: Article

References (39)

1. Alemany, R., Balagué, C., and Curiel, D.T. (2000). Replicative adenoviruses for cancer therapy. Nat. Biotechnol. 18, 723-727. (Pubitemid 30460686)
2. Barker, D.D., and Berk, A.J. (1987). Adenovirus proteins from both E1B reading frames are required for transformation of rodent cells by viral infection and DNA transfection. Virology 156, 107-121. (Pubitemid 17013653)
3. Bischoff, J.R., Kirn, D.H., Williams, A., et al. (1996). An adeno-virus mutant that replicates selectively in p53-deficient human tumor cells. Science 274, 373-376. (Pubitemid 26353341)
4. Fields, B.N., and Hawkins, K. (1967). Human infection with virus of vesicular stomatitis during an epizootic. N. Engl. J. Med. 277, 989-994.
5. Fueyo, J., Gomez-Manzano, C., Alemany, R., et al. (2000). A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene 19, 2-12. (Pubitemid 30066345)
6. Gainey, M.D., Manuse, M.J., and Parks, G.D. (2008). A hy-perfusogenic F protein enhances the oncolytic potency of a paramyxovirus simian virus 5 P/V mutant without compromising sensitivity to type I interferon. J. Virol. 82, 9369-9380.
7. Ganly, I., Kirn, D., Eckhardt, G., et al. (2000). A phase I study of Onyx-015, an E1B attenuated adenovirus, administered in-tratumorally to patients with recurrent head and neck cancer. Clin. Cancer Res. 6, 798-806. (Pubitemid 30159332)
8. Giedlin, M.A., Cook, D.N., and Dubensky, T.W., Jr. (2003). Vesicular stomatitis virus: An exciting new therapeutic oncolytic virus candidate for cancer or just another chapter from Fields Virology? Cancer Cell 4, 241-243. (Pubitemid 37329785)
9. Graham, F.L., Smiley, J., Russell, W.C., et al. (1977) Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J. Gen. Virol. 36, 59-74.
10. Hallenbeck, P.L., Chang, Y.N., Hay, C., et al. (1999). A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. Hum. Gene Ther. 10, 1721-1733. (Pubitemid 29328216)
11. Hardcastle, J., Kurozumi, K., Chiocca, E.A., et al. (2007). Onco-lytic viruses driven by tumor-specific promoters. Curr. Cancer Drug Targets 7, 181-189. (Pubitemid 46348633)
12. Heise, C., Sampson-Johannes, A., Williams, A., et al. (1997). ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat. Med. 3, 639-645. (Pubitemid 27264973)
13. Kasuya, H., Takeda, S., Nomoto, S., et al. (2005). The potential of oncolytic virus therapy for pancreatic cancer. Cancer Gene Ther. 12, 725-736. (Pubitemid 41208612)
14. Khuri, F.R., Nemunaitis, J., Ganly, I., et al. (2000). A controlled trial of intratumoral ONYX-015, a selectively-replicating ade-novirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat. Med. 6, 879-885. (Pubitemid 30644745)
15. Kirn, D., Martuza, R.L., and Zwiebel, J. (2001). Replication-selective virotherapy for cancer: Biological principles, risk management and future directions. Nat. Med. 7, 781-787. (Pubitemid 32691631)
16. Kuhn, I., Harden, P., Bauzon, M., et al. (2008). Directed evolution generates a novel oncolytic virus for the treatment of colon cancer. PLoS One 3, e2409.
17. Letchworth, G.J., Rodriguez, L.L., and Del Cbarrera, J. (1999). Vesicular stomatitis. Vet. J. 157, 239-260. (Pubitemid 129524048)
18. Martuza, R.L., Malick, A., Markert, J.M., et al. (1991). Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252, 854-856. (Pubitemid 121000529)
19. Mineta, T., Markert, J.M., Takamiya, Y., et al. (1994). CNS tumor therapy by attenuated herpes simplex viruses. Gene Ther. 1(Suppl. 1), S78.
20. Mineta, T., Rabkin, S.D., Yazaki, T., et al. (1995). Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat. Med. 1, 938-943.
21. Miyatake, S.I., Tani, S., Feigenbaum, F., et al. (1999). Hepatoma-specific antitumor activity of an albumin enhancer/promoter regulated herpes simplex virus in vivo. Gene Ther. 6, 564-572. (Pubitemid 29192665)
22. Nemunaitis, J., Ganly, I., Khuri, F., et al. (2000). Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res. 60, 6359-6366.
23. Parry, C.M., Simas, J.P., Smith, V.P. et al. (2000). A broad spectrum secreted chemokine binding protein encoded by a her-pesvirus. J. Exp. Med. 191, 573-578.
24. Quiroz, E., Moreno, N., Peralta, P.H., et al. (1988). A human case of encephalitis associated with vesicular stomatitis virus (Indiana serotype) infection. Am. J. Trop. Med. Hyg. 39, 312-314.
25. Rainov, N.G., and Ren, H. (2003). Oncolytic viruses for treatment of malignant brain tumours. Acta Neurochir. Suppl. 88, 113-123.
26. Raykov, Z., Grekova, S., Leuchs, B., et al. (2008). Arming par-voviruses with CpG motifs to improve their oncosuppressive capacity. Int. J. Cancer 122, 2880-2884. (Pubitemid 351631394)
27. Rose, J.A., and Whitt, M.A. (2001). Rhabdoviridae: The viruses and their replication. In: Knipe, H.P., and Howley, P.M., Fields Virology. (Philadelphia, Lippincott, Williams & Wilkins) pp. 1221-1242.
28. Shinozaki, K., Ebert, O., and Woo, S.L. (2005). Eradication of advanced hepatocellular carcinoma in rats via repeated hepatic arterial infusions of recombinant VSV. Hepatology 41, 196-203. (Pubitemid 40066398)
29. NTR nitroreductase-armed oncolytic adenovirus. Cancer Gene Ther. 14, 953-967. (Pubitemid 350115355)
30. Stojdl, D.F., Lichty, B., Knowles, S., et al. (2000a). Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat. Med. 6, 821-825. (Pubitemid 30469434)
31. Stojdl, D.F., Abraham, N., Knowles, S., et al. (2000b). The murine double-stranded RNA-dependent protein kinase PKR is required for resistance to vesicular stomatitis virus. J. Virol. 74, 9580-9585.
32. Sudia, W.D., Fields, B.N., et al. (1967). Isolation of vesicular stomatitis virus (Indiana strain) and other viruses from mosquitoes in New Mexico 1965. Am. J. Epidemiol. 86, 598-602.
33. Thorne, S.H., Hwang, T.H., O'Gorman, W.E., et al. (2007). Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963. J. Clin. Invest. 117, 3350-3358. (Pubitemid 350096991)
34. van Berkel, V., Barrett, J., Tiffany, H.L. et al. (2000). Identification of a gammaherpesvirus selective chemokine binding protein that inhibits chemokine action. J. Virol. 74, 6741-6747. (Pubitemid 30470656)
35. Whitley, R.J., Kern, E.R., Chatterjee, S., et al. (1993). Replication, establishment of latency, and induced reactivation of herpes simplex virus gamma 1 34.5 deletion mutants in rodent models. J. Clin. Invest. 91, 2837-2843. (Pubitemid 23182543)
36. Wickham, T.J., Tzeng, E., et al. (1997). Increased in vitro and in vivo gene transfer by adenovirus vectors containing chi-meric fiber proteins. J. Virol. 71, 8221-8229. (Pubitemid 27446397)
37. Wu, L., Huang, T.G., Meseck, M., et al. (2008). rVSV(MD51)-M3 is an effective and safe oncolytic virus for cancer therapy. Hum. Gene Ther. 19, 635-647. (Pubitemid 351913526)
38. Xie, M., Niu, J.H., Chang, Y., et al. (2009). A novel triple-regulated oncolytic adenovirus carrying PDCD5 gene exerts potent antitumor efficacy on common human leukemic cell lines. Apoptosis 14, 1086-1094.
39. Ziauddin, M.F., Guo, Z.S., O'Malley, M.E., et al. (2010). TRAIL gene-armed oncolytic poxvirus and oxaliplatin can work synergistically against colorectal cancer. Gene Ther. 17, 550-559.